<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01632020</url>
  </required_header>
  <id_info>
    <org_study_id>134190</org_study_id>
    <nct_id>NCT01632020</nct_id>
  </id_info>
  <brief_title>Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth</brief_title>
  <official_title>Pilot Study: Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of short term oral Metformin therapy
      on biomarkers for tumor growth in subjects with newly diagnosed colon or rectal
      adenocarcinoma.

      It is hypothesized that there are independent actions of Metformin on the outcome of subjects
      with colorectal cancer (CRC). Also hypothesized is that metformin effects on CRC cell growth
      will correlate with this drug's effects on markers mentioned above, because the markers are
      closely related to tumor growth and metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blinded placebo controlled clinical investigation of the effects
      of short term oral Metformin therapy on biomarkers for tumor growth in subjects with newly
      diagnosed colon or rectal adenocarcinoma. Metformin is a well-tolerated drug widely
      prescribed for treatment of Type 2 diabetes mellitus. Preliminary studies have generated the
      hypothesis that metformin may have positive effects on both prevention and survival of colon
      cancer subjects. Clinical trials are ongoing to explore this possibility in breast cancer
      (NCT01101438). This investigation is the first study of Metformin in colorectal cancer (CRC)
      patients, and is designed to understand the mechanism of its anti-cancer actions, if any, and
      its interactions with biomarkers in colorectal cancer patients.

      Based upon epidemiological studies, it is hypothesized that there are independent actions of
      Metformin on the outcome of subjects with CRC. Also hypothesized is that metformin effects on
      CRC cell growth will correlate with this drug's effects on markers mentioned above, because
      the markers are closely related to tumor growth and metastases.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inadequate accrual
  </why_stopped>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proliferation Status of CRC Tumor and Adjacent Normal Tissue Following Metformin Therapy</measure>
    <time_frame>10-21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mucosal Apoptotic Status of CRC Tumor and Adjacent Normal Tissue Following Metformin Therapy</measure>
    <time_frame>10-21 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>inactive drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
    <other_name>Glucophage XR</other_name>
    <other_name>Glumetza</other_name>
    <other_name>Fortamet</other_name>
    <other_name>Riomet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, all races and ethnicities are eligible

          -  Age equal to or greater than 18 years of age

          -  All subjects should have a pathological/histological diagnosis of colorectal cancer.

          -  Clinical diagnosis of stage I, II, III or IV colon cancer or stage I, II, III or IV
             rectal cancer; cancer may be primary including a secondary primary

          -  Candidate for elective surgery(for removal of primary) or endoscopic biopsy

          -  ECOG Performance status of 0 - 2

          -  Adequate renal, liver, and bone marrow function

          -  Hb: (adequate for surgical intervention, with transfusion if necessary)

          -  WBC: (normal range)

          -  Platelets: (180K/cmm)

          -  LFTs: Normal bilirubin (&lt; 2.0mg/dL), AST/ALT (2xULN)

          -  Renal function: normal creatinine

          -  Subjects must have signed informed consent

          -  Female subjects must either not be of child-bearing potential or must have a negative
             urine pregnancy test within 7 days of beginning the drug or placebo treatment.
             Subjects are considered not of child-bearing potential if they are surgically sterile
             or they are postmenopausal for greater than 12 months.

        Exclusion Criteria:

          -  Previously diagnosed with diabetes mellitus Type 1 or Type 2.

          -  Currently taking biguanides, sulfonylurea drugs, thiazolidinediones, insulin, or mTOR
             inhibitors or having taken any of these medications during the 12 weeks prior to study
             participation.

          -  Currently taking any non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin and
             unable to stop such medications due to a present medical condition.

          -  Clinical symptoms of gastrointestinal obstruction or bleeding and consideration for
             immediate surgery or immediate neoadjuvant chemoradiation.

          -  Familial Adenomatous Polyposis (FAP), hereditary non-polyposis colorectal cancer
             (HNPCC), Putz-Jeghers disease, ulcerative colitis, or Crohn's disease.

          -  Pregnant or lactating.

          -  History of lactic or other metabolic acidosis.

          -  Known hypersensitivity to Metformin.

          -  Uncontrolled infectious disease.

          -  History of Positivity for human immunodeficiency virus (HIV).

          -  History of congestive heart failure requiring pharmacologic treatment.

          -  History of excessive alcohol abuse, defined by a habitual intake of more than three
             drinks daily.

          -  Previous or concurrent malignancies, except non-melanoma skin cancers, unless
             curatively treated and with no evidence of recurrence for &gt; 5 years, with the
             exception of prior CRC which has been treated and the patient has been in remission
             and the current primary tumor is a second CRC.

          -  Unable to swallow and retain oral medication.

          -  Mal-absorption syndrome, disease affecting gastrointestinal function, or previous
             resection of the stomach or small bowel.

          -  Current use of medications for weight loss.

          -  Currently taking cimetidine, thiazide diuretics or cephalexin. If a patient needs some
             of these agents, alternative agents should be substituted.

          -  If the physician feels that the candidate is not suitable for the study, he/she will
             be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rangaswamy Govindarajan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Simmen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Arkansas Veterans Heathcare System</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2012</study_first_submitted>
  <study_first_submitted_qc>June 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2012</study_first_posted>
  <results_first_submitted>February 19, 2016</results_first_submitted>
  <results_first_submitted_qc>May 31, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 11, 2016</results_first_posted>
  <last_update_submitted>May 31, 2016</last_update_submitted>
  <last_update_submitted_qc>May 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal tumor</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>colorectal carcinoma</keyword>
  <keyword>neoplasms, colorectal</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was open for enrollment between 7/13/2012 and 3/5/2014. Subjects were recruited from medical clinics at the University of Arkansas for Medical Sciences (UAMS) and the Central Arkansas Veterans Healthcare System (CAVHS).</recruitment_details>
      <pre_assignment_details>There were no significant events following participant enrollment, prior to group assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo: 2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days</description>
        </group>
        <group group_id="P2">
          <title>Metformin</title>
          <description>Metformin: 850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo: 2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days</description>
        </group>
        <group group_id="B2">
          <title>Metformin</title>
          <description>Metformin: 850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="52" upper_limit="61"/>
                    <measurement group_id="B2" value="44" lower_limit="37" upper_limit="54"/>
                    <measurement group_id="B3" value="49" lower_limit="37" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proliferation Status of CRC Tumor and Adjacent Normal Tissue Following Metformin Therapy</title>
        <time_frame>10-21 days</time_frame>
        <population>Data not collected due to inadequate subject accrual. Analysis not completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin: 850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Proliferation Status of CRC Tumor and Adjacent Normal Tissue Following Metformin Therapy</title>
          <population>Data not collected due to inadequate subject accrual. Analysis not completed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mucosal Apoptotic Status of CRC Tumor and Adjacent Normal Tissue Following Metformin Therapy</title>
        <time_frame>10-21 days</time_frame>
        <population>Data not collected due to inadequate subject accrual. Analysis not completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin: 850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mucosal Apoptotic Status of CRC Tumor and Adjacent Normal Tissue Following Metformin Therapy</title>
          <population>Data not collected due to inadequate subject accrual. Analysis not completed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo: 2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days</description>
        </group>
        <group group_id="E2">
          <title>Metformin</title>
          <description>Metformin: 850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdomen Pain Not Otherwise Specified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain of the extremities/ limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects. Outcome measures not computed because data would not be statistically relevant.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Daisy Wade</name_or_title>
      <organization>University of Arkansas for Medical Sciences</organization>
      <phone>5016868274</phone>
      <email>dewade@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

